Mineralys Therapeutics (MLYS) Change in Acquisitions & Divestments (2022 - 2026)

Mineralys Therapeutics has reported Change in Acquisitions & Divestments for 5 years, with the latest figure at $302.5 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 764.29% year-over-year to $302.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $692.5 million (up 51.86% YoY) and the FY2025 annual result came in at $425.0 million, down 13.0% from the prior year.
• Change in Acquisitions & Divestments rose to $302.5 million in Q1 2026 per MLYS's latest filing, from $165.0 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $302.5 million in Q1 2026 and troughed at $22.5 million in Q1 2023.
• A 5-year average of $103.8 million and a median of $71.2 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2025 and 2026: Change in Acquisitions & Divestments plunged 48.15% in 2025, then surged 764.29% in 2026.
• Over 5 years, Change in Acquisitions & Divestments stood at $50.0 million in 2022, then increased by 30.0% to $65.0 million in 2023, then jumped by 126.92% to $147.5 million in 2024, then increased by 11.86% to $165.0 million in 2025, then surged by 83.33% to $302.5 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $302.5 million, $165.0 million, and $150.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.